Goldman Sachs analyst Chris Shibutani initiated coverage of Ventyx Biosciences with a Buy rating and $50 price target. Ventyx’s "fast-follower" approach developing potentially best-in-class therapies for validated therapeutic targets will translate to meaningful opportunities in the "commercially attractive" immunology and inflammation space, Shibutani tells investors in a research note. The analyst sees potential share catalysts in the company’s January 26 R&D day and Phase 2 readouts of VTX958 in plaque psoriasis and psoriatic arthritis.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VTYX:
- Takeda deal has positive read through for Ventyx, says Piper
- Ventyx Biosciences doses first patient in VTX958 trial
- Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis
- Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
